C4X DISCOVERY HOLDINGS PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12 GBX | +27.32% |
|
+45.90% | +33.33% |
| 04-25 | Norcros sells Johnson Tiles UK; Trifast trading well | AN |
| 04-25 | C4X Discovery Set for Friday Delisting from London Bourse's AIM | MT |
| Sales 2024 * | 30.23M 37.76M 3.02B | Sales 2025 * | 5.93M 7.41M 593M | Capitalization | 30.27M 37.81M 3.03B |
|---|---|---|---|---|---|
| Net income 2024 * | 17M 21.24M 1.7B | Net income 2025 * | -6M -7.5M -600M | EV / Sales 2024 * | 0.27 x |
| Net cash position 2024 * | 22.23M 27.77M 2.22B | Net cash position 2025 * | 15.76M 19.69M 1.58B | EV / Sales 2025 * | 2.45 x |
| P/E ratio 2024 * |
1.74
x | P/E ratio 2025 * |
-4.29
x | Employees | 49 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 69.24% |
More Fundamentals
* Assessed data
More news
Latest transcript on C4X Discovery Holdings plc
More press releases
| 1 day | +27.32% | ||
| 1 week | +45.90% | ||
| Current month | +24.48% | ||
| 1 month | -9.09% | ||
| 3 months | -9.09% | ||
| 6 months | -15.94% | ||
| Current year | +33.33% |
1 week
7.00
12.00
1 month
7.0012.00
Current year
7.0019.60
1 year
7.0022.00
3 years
7.0047.90
5 years
7.0061.60
10 years
7.00150.00
| Managers | Title | Age | Since |
|---|---|---|---|
Clive Dix
CEO | Chief Executive Officer | 70 | 02/09/14 |
Bradley Hoy
DFI | Director of Finance/CFO | 61 | 21/11/16 |
Nick Ray
CTO | Chief Tech/Sci/R&D Officer | - | 31/12/15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Clive Dix
CEO | Chief Executive Officer | 70 | 02/09/14 |
Simon Harford
BRD | Director/Board Member | 64 | 19/04/21 |
| Director/Board Member | 53 | 02/09/14 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 25/04/24 | 12 | +27.32% | 3,770,461 |
| 24/04/24 | 9.425 | +4.72% | 1,748,773 |
| 23/04/24 | 9 | +10.09% | 1,749,143 |
| 22/04/24 | 8.175 | -0.61% | 19,537,860 |
| 19/04/24 | 8.225 | -3.80% | 1,024,803 |
Delayed Quote London S.E., April 25, 2024 at 04:46 pm
More quotes
C4X Discovery Holdings plc is a drug discovery company. The Company has a portfolio ranging from early-stage target opportunities to late-stage drug discovery programs. The Company has three commercially partnered programs with one candidate in clinical development. Its portfolio focuses on treatments for immuno-inflammatory diseases. The Companyâs pipeline products include MALT-1 Inhibitor, a4B7 Integrin Inhibitor, IL-17A Inhibitor, NRF-2 Activator, and others. Its target identification platform (Taxonomy3) is used to analyze complex genetic datasets to identify and characterize drug target candidates. Taxonomy3 offers the potential for patient stratification in clinical trials, ensuring patient targeting and the potential for rescuing failed clinical trials or for drug repurposing. PatientSeek is its new platform that applies the mathematical approach of Taxonomy3 to stratify patients for treatments based on their genetics.
Calendar
11/12/2024
- Q4 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.12
GBP
Average target price
0.48
GBP
Spread / Average Target
+300.00%
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +33.33% | 37.7M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- C4XD Stock
